2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Cell Expansion, Treatment Considerations, Drug Development, Biological Therapies, Natural Killer (NK) Cell Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Pharmacology, Biological Processes, Immune Mechanism, Diseases, Bleeding and Clotting, Platelet Disorders, Immunology, Autoimmune Disorders, Autoimmune Hemolytic Anemia, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Non-Hodgkin Lymphoma, T Cell Lymphoma, Research, Fundamental Science, AML, Translational Research, Study Population, Human, Animal Model
PAPER

2377 Engineering hematopoietic stem and progenitor cells to generate universal, low-toxicity CAR-NKT cell therapies for autoimmune diseases

Yan-Ruide Li, PhD, Yuning Chen2, Yichen Zhu3, Xinyuan Shen4
1 University of California, Los Angeles, Los Angeles, California, United States
2 University of California, Los Angeles, Los Angeles, California, United States
3 University of California, Los Angeles, Los Angeles, California, United States
4 University of California, Los Angeles, Los Angeles, California, United States

Background: Chimeric antigen receptor (CAR)-T cell therapies have demonstrated remarkable efficacy in B cell-mediated autoimmune diseases but are associated with significant limitations, including cytokine release syndrome (CRS), neurotoxicity, autologous manufacturing, and limited scalability. Invariant natural killer T (NKT) cells possess intrinsic immunoregulatory functions, exhibit minimal risk of graft-versus-host disease, and can be developed as allogeneic off-the-shelf cellular products. We hypothesized that hematopoietic stem and progenitor cell (HSPC) engineering could enable scalable generation of universal CAR-NKT cells with superior safety and therapeutic efficacy for autoimmune diseases, including multiple sclerosis.

Methods: Human HSPCs were genetically engineered to express a CD19-targeting CAR construct and differentiated into CAR-NKT cells using an optimized clinically-guided feeder-free differentiation platform. Cellular phenotype, purity, and expansion were evaluated by flow cytometry. Therapeutic efficacy was assessed in human CD19+ B-cell malignancy xenograft mouse models. Cytotoxicity against autoreactive immune cells, cytokine production, and safety were evaluated using in vitro functional assays and humanized NSG-SGM3 mice.

Results: CAR-NKT cells generated from engineered HSPCs exhibited robust expansion, high purity, and a mature invariant NKT-cell phenotype suitable for clinical-scale manufacturing. In a experimental autoimmune encephalomyelitis (EAE) model, murine CD19-targeting CAR-NKT cells significantly outperformed conventional CAR-T cells in suppressing disease progression and reducing neurological symptoms. Human allogeneic CD19-targeting CAR-NKT cells efficiently eliminated CD19+ autoreactive B cells and proinflammatory CD1d+ myeloid cells while preserving favorable immune homeostasis. Importantly, HSPC-derived CAR-NKT cells maintained potent cytotoxic activity in RAJI human CD19+ B-cell malignancy xenograft mouse models. In humanized NSG-SGM3 mice, CAR-NKT therapy induced substantially lower CRS-associated cytokine release compared with conventional CAR-T cells, supporting an improved safety profile. These findings demonstrate that HSPC engineering enables the production of universal CAR-NKT cells with potent immunoregulatory function, scalable manufacturing potential, and reduced treatment-related toxicity.

Conclusions: We developed a clinically translatable HSPC engineering platform capable of generating universal, off-the-shelf CAR-NKT cells for autoimmune diseases. HSPC-derived CAR-NKT cells demonstrated superior therapeutic efficacy compared with CAR-T cells in preclinical autoimmune models while maintaining a markedly improved safety profile. This work establishes engineered CAR-NKT cells as a promising next-generation adoptive cellular therapy for autoimmune diseases and supports their further clinical development.

Yan-Ruide Li, PhD: No relevant conflicts of interest to declare.